LDS/Medical Tests/Carnitine-Acylcarnitine Translocase Deficiency, Gene Mutation Analysis

Carnitine-Acylcarnitine Translocase Deficiency, Gene Mutation Analysis

Carnitine-Acylcarnitine Translocase (CACT) is located on the short arm of chromosome 3 (3p21.31) and belongs to SLC25 gene family, SLC25A20 and is mainly expressed in heart, liver, and skeletal muscle. The enzyme carnitine-acylcarnitine translocase is essential for the transport of long-chain fatty acids into mitochondria.

CACT Deficiency is a rare autosomal recessive disorder. CACT and severe CPT2 deficiency have identical clinical manifestations and blood acylcarnitine profiles in the neonatal period and are difficult to differentiate. Neonates with CACT Deficiency manifest with hypoketotic hypoglycemia, neurological damage, cardiomyopathy, hepatic failure, skeletal myopathy, rhabdomyolysis, renal dysfunction, hyperammonemia, coma and death.

  • Confirmation of CACT deficiency.
  • Carrier screening for CACT deficiency
  • Prenatal diagnosis of CACT deficiency
Heterozygous status indicates that an individual is a carrier and homozygous status indicates CACT deficiency.

Negative for mutation analyze (No reportable variants were identified)

Polymerase chain reaction, Conventional sequencing, Next Generation Sequencing (NGS) Gene-targeted deletion/duplication analysis, gel electrophoresis.

Whole blood in EDTA

Stability

  • Room: 3-5 days
  • Refrigerated: 7-14 days
  • Other specimens: Saliva, Buccal swab, skin biopsy.
CPT2 genotyping.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login